CO2021006672A2 - Moduladores de nlrp3 - Google Patents

Moduladores de nlrp3

Info

Publication number
CO2021006672A2
CO2021006672A2 CONC2021/0006672A CO2021006672A CO2021006672A2 CO 2021006672 A2 CO2021006672 A2 CO 2021006672A2 CO 2021006672 A CO2021006672 A CO 2021006672A CO 2021006672 A2 CO2021006672 A2 CO 2021006672A2
Authority
CO
Colombia
Prior art keywords
nlrp3
modulators
nlrp3 modulators
compounds
medicaments
Prior art date
Application number
CONC2021/0006672A
Other languages
English (en)
Inventor
Yong Zhang
Jay A Markwalder
Ashvinikumar V Gavai
Shomir Ghosh
William R Roush
Andrew F Donnell
Prasanna Sivaprakasam
Steven P Seitz
Original Assignee
Innate Tumor Immunity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66677224&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2021006672(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Tumor Immunity Inc filed Critical Innate Tumor Immunity Inc
Publication of CO2021006672A2 publication Critical patent/CO2021006672A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de Fórmula (I): (I) en el que todas las variables son como se definen en el presente documento. Estos compuestos son moduladores de NLRP3, que pueden ser utilizados como medicamentos para el tratamiento de trastornos proliferativos, tales como cáncer en un sujeto (por ejemplo, un ser humano).
CONC2021/0006672A 2018-04-25 2020-10-21 Moduladores de nlrp3 CO2021006672A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862662240P 2018-04-25 2018-04-25
US201862764818P 2018-08-16 2018-08-16
US201962825044P 2019-03-28 2019-03-28
PCT/US2019/028823 WO2019209896A1 (en) 2018-04-25 2019-04-24 Nlrp3 modulators

Publications (1)

Publication Number Publication Date
CO2021006672A2 true CO2021006672A2 (es) 2021-06-10

Family

ID=66677224

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2021/0006672A CO2021006672A2 (es) 2018-04-25 2020-10-21 Moduladores de nlrp3
CONC2020/0013155A CO2020013155A2 (es) 2018-04-25 2020-10-21 Moduladores de nlrp3

Family Applications After (1)

Application Number Title Priority Date Filing Date
CONC2020/0013155A CO2020013155A2 (es) 2018-04-25 2020-10-21 Moduladores de nlrp3

Country Status (17)

Country Link
US (1) US20210267964A1 (es)
EP (2) EP4353235A2 (es)
JP (2) JP7351850B2 (es)
KR (1) KR20210005106A (es)
CN (2) CN112074516A (es)
AU (1) AU2019261582A1 (es)
BR (1) BR112020021539A2 (es)
CA (1) CA3097865A1 (es)
CL (1) CL2020002719A1 (es)
CO (2) CO2021006672A2 (es)
IL (1) IL278173A (es)
MX (1) MX2020011234A (es)
PE (1) PE20210160A1 (es)
SG (1) SG11202010463TA (es)
TW (1) TW202014420A (es)
WO (1) WO2019209896A1 (es)
ZA (1) ZA202007307B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
CR20220584A (es) * 2020-04-16 2023-02-15 Incyte Corp Inhibidores de kras tricíclicos fusionados
JP2023523756A (ja) 2020-04-30 2023-06-07 ヤンセン ファーマシューティカ エヌ．ベー． 新規なトリアジノインドール化合物
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
WO2022037631A1 (zh) * 2020-08-21 2022-02-24 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
EP3984535A1 (en) * 2020-10-16 2022-04-20 Albert-Ludwigs-Universität Freiburg Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
CN114539095A (zh) * 2020-11-26 2022-05-27 乐凯化学材料有限公司 3-（4-羟基-3-甲氧基-苯基）-2-氰基-2-丙烯酸乙酯的制备方法
US11939328B2 (en) 2021-10-14 2024-03-26 Incyte Corporation Quinoline compounds as inhibitors of KRAS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
EP2112166B1 (en) 1998-12-23 2018-11-21 Pfizer Inc. Human monoclonal antibodies to ctla-4
DE60033530T2 (de) 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20070259907A1 (en) * 2004-06-18 2007-11-08 Prince Ryan B Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
BR122021025338B1 (pt) 2009-11-24 2023-03-14 Medimmune Limited Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
PL2573073T3 (pl) 2011-09-26 2015-04-30 Sanofi Sa Pochodne pirazolochinolinonu, ich wytwarzanie i ich zastosowanie terapeutyczne
HUE051954T2 (hu) 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2013181634A2 (en) 2012-05-31 2013-12-05 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
DK2992017T3 (da) 2013-05-02 2021-01-25 Anaptysbio Inc Antistoffer rettet mod programmeret død-1 (pd-1)
MX354057B (es) 2013-05-18 2018-02-09 The Regents Of The Univ Of California Star Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón".
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
CN104418867B (zh) * 2013-08-26 2016-12-28 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途
CN107011441B (zh) 2013-09-13 2020-12-01 百济神州(广州)生物科技有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
PT3081576T (pt) 2013-12-12 2019-10-15 Jiangsu Hengrui Medicine Co Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
PT3303394T (pt) 2015-05-29 2020-07-01 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
CN105523955B (zh) * 2015-12-14 2018-08-17 北京嘉林药业股份有限公司 化合物及其在制备药物中的用途
WO2017132825A1 (zh) 2016-02-02 2017-08-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017184735A1 (en) * 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
BR112018071347A2 (pt) * 2016-04-19 2019-02-05 Innate Tumor Immunity Inc moduladores de nlrp3

Also Published As

Publication number Publication date
AU2019261582A1 (en) 2020-11-12
ZA202007307B (en) 2023-01-25
JP7351850B2 (ja) 2023-09-27
CN112521387A (zh) 2021-03-19
CL2020002719A1 (es) 2020-12-18
CN112074516A (zh) 2020-12-11
PE20210160A1 (es) 2021-01-26
JP2021522249A (ja) 2021-08-30
EP3784670B1 (en) 2023-11-29
IL278173A (en) 2020-11-30
TW202014420A (zh) 2020-04-16
US20210267964A1 (en) 2021-09-02
CN112521387B (zh) 2023-08-22
WO2019209896A1 (en) 2019-10-31
SG11202010463TA (en) 2020-11-27
MX2020011234A (es) 2020-11-11
BR112020021539A2 (pt) 2021-01-19
JP2024001030A (ja) 2024-01-09
EP4353235A2 (en) 2024-04-17
KR20210005106A (ko) 2021-01-13
CA3097865A1 (en) 2019-10-31
CO2020013155A2 (es) 2021-06-10
EP3784670A1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
CO2020013155A2 (es) Moduladores de nlrp3
CO2020000227A2 (es) Moduladores de nlrp3
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018002759A1 (es) Compuestos de pirrolotriazina como inhibidores de tam.
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CO2018005954A2 (es) Compuestos heteroaromáticos como inhibidores de btk
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
CO2017005959A2 (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
CO2019013016A2 (es) Inhibidores pirazólicos de magl
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CL2019003515A1 (es) Compuestos heteroaromáticos como inhibidores de vanina.
DOP2021000071A (es) Compuestos heteroaromáticos como inhibidores de vanina
DOP2021000021A (es) Compuestos heteroaromáticos como inhibidores de vanina
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CL2020001093A1 (es) Proceso para preparar el benzotiofen-2-il boronato.
EA202090283A1 (ru) Модуляторы nlrp3
EA202092539A1 (ru) Модуляторы nlrp3
MX2020004871A (es) Derivados de acido cafeico y sus usos.
CR20190110A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1